This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Flora Growth Corp.
5/10/2022
Greetings and welcome to the Flora Growth first half 2021 conference call. At this time, all participants are in a listen-only mode and this conference is being recorded. Following their initial formal remarks, Flora Growth will conduct a question and answer session. Webcast participants can submit a question directly through the webcast. Further instructions will be provided as the Q&A begins. The host of today's call will be Evan Verriard, Flora Growth's Vice President of Investor Relations. On the call with him today with prepared remarks are Louise Marchand, Chief Executive Officer, Jason Warnock, Chief Revenue Officer, Director and Lead Scientific Advisor, Dr. Annabelle Manalo-Morgan, James Williams, VP of Corporate Development, and Lee Lederman, Chief Financial Officer. They will be discussing the results for the first half of fiscal year 2021 and answering related questions. As a reminder, our first half earnings release was issued after market closed today, and a copy of that press release can be found in the Investor Center on FLORA's website and EDGAR. Now, I will turn over the call to our host, Evan Berriard.
Thank you, Operator. I would like to note that during this call, management's prepared remarks may contain forward-looking statements within the meaning of applicable securities legislation, and management may make additional forward-looking statements during the Q&A session. Forward-looking statements may include, but are not limited to, statements with respect to Florida's financial performance, growth in revenue and earnings, and business prospects and opportunities. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from the conclusions, forecasts, or projections expressed or implied by such forward-looking statements. These statements do not guarantee future performance, and therefore, undue reliance should not be placed upon them. certain material factors and assumptions have been applied in drawing the conclusions or making forecasts or projections reflected in such forward-looking statements. A description of the factors that could affect and the assumptions underlying Flora's forward-looking statements can be found in the risk factors contained in Flora's fiscal 2021 first half financial results press release and in Flora's filings with the Securities Exchange Commission. Flora undertakes no obligation to publicly correct or update the forward-looking statements made during the presentation to reflect future events or circumstances, except as may be required under applicable securities laws. At this time, it is my pleasure to introduce Flora Growth's Chief Executive Officer, Luis Marchand.
Thank you, Evan. Welcome, everyone, to Flora Growth's first earnings call. Thank you to all of the participants for your interest in Flora. Today, my team and I will comment on the first half 2021 results as well as provide color on second half expectations with a focus on three key components to Flora's strategy. The developments that occurred with our wholesale cannabis operations, our robust M&A strategy, and an outlook on the expansion of our product portfolio. As a foreign private issuer, we are only required to submit financial results on a half-year basis, where we have six months to file the unedited results in order to maintain a high degree of transparency with the investor community, we have chosen to move forward the communication of this information and release results and forward-looking guidance today. Our full financials will be filed with the SEC within the following weeks. As these are our first financial results as a public company, we want to be 100% sure that our financials are in full compliance with all required standards and fairly represent our business the way it functions. To begin, as it is our first earnings call as a public company, it's important to provide some background on Flora Growth. At the beginning of 2020, Flora launched a Regulation A-plus offering, and through the course of the year, we completed a $30 million financing and brought in over 10,000 investors in the process. Across 2020, Flora Growth was largely a pre-revenue company, where we announced a number of important transactions, launched multiple divisions and brands, assembled a key operating team, and built the foundation from which we are growing the business today. Since the beginning of 2021, we've had a very excited year at Flora. On May 11th, we completed our IPO listing on the Nasdaq Exchange, becoming the first cannabis company to complete an IPO on an American exchange without a SPAC, reverse merger, or dual listing. Since then, we have been working diligently to position Flora for growth that aligns with our strategic view of the global cannabis market. Flora's strategy is to leverage our natural outdoor cultivation practices to manufacture cannabis derivatives at a competitive cost structure, to develop a product portfolio across multiple industries that will be disrupted by cannabis, and to seek revenue-generating acquisitions and partnerships that offer an accretive distribution network and complement our human capital. Our Cozichemos cultivation facility in Bucaramanga, Colombia, with 247 acres licensed for cultivation, yields demonstrated production costs below $0.06 per gram of dry flour. which is achieved through a combination of geographic factors, including natural water reserves, organic nutrient-rich soil, and 12.5 hours of sunlight, 365 days per year. From a quality perspective, we are in the process of obtaining a GACP and organic certifications, as well as building a extraction facility to EU GMP standards. These standards will give us access to the wholesale cannabis market across the globe. while our low cultivation costs will ensure we remain highly competitive now and in the future. Further, Flora is building an expansive distribution network for its existing product portfolio of cannabinoid and non-cannabinoid-based products, where we are currently selling in over 10 different countries, including the United States, Costa Rica, and the United Kingdom, to name a few. At this time, Flora is focused on aggressively expanding its distribution network across different markets and categories. where we will then look to leverage those channels with additional product SKUs or brands to amplify revenue growth. A perfect illustration of this strategy is our agreement with Tropi, Colombia's largest food and beverage distributor with over 130,000 distribution points, where our goal is to introduce our entire product portfolio across our network. At this time, I would also like to comment on Flora Growth's adherence to robust corporate governance. Flora's board functions to ensure the correct management team is in place, that the strategic direction is correct, and to provide strict oversight on management's actions and performance. We feel confident that we have the correct board in place and the correct controls to ensure effective oversight. Our board is led by Bernie Wilson, a former vice chairman of PWC and current chairman of the Founders Board of the Institute of Corporate Directors. and our board is comprised of four independent directors with relevant backgrounds in medical cannabis, CPG, and corporate governance. With Bernie's guidance, we have formed a number of committees, including an audit committee, a compensation committee, and a nomination and corporate governance committee, which ensure Flora Growth operates in a responsible and efficient manner and in accordance with our various corporate policies. Investors can find Flora Growth's corporate documents, including code of conduct, whistleblower policy, trading policies, and anti-bribery and anti-corruption policy under the Investor Center on our website. Later on this call, our CFO will be sharing some insight into our financial performance over the course of the first half of the year. However, I am encouraged to share some of the results for the period, as well as provide revenue guidance to our shareholders for the first time. While we are only halfway through our first revenue generating year, I am pleased to report that our unaudited net revenues exceeded our original internal estimates at the start of 2021. We have already surpassed the 2 million mark as compared to approximately 100,000 for the entire year of 2020. This is complemented by a strong gross margin of approximately 60%, a mark we're proud of as an early stage company. To put this into perspective, our recently completed sales agreement from Tropy totaled approximately $1.1 million for the first order alone, giving us confidence that we can achieve strong growth moving forward. These first half results were driven largely by the growth of our operating divisions in Colombia and the US, and achieved in the face of major headwinds in Colombia from the COVID-19 pandemic. As it relates to the COVID-19 pandemic, we continue to monitor the situation closely in Colombia and the other countries in which we operate. Although it remains a risk that all companies must manage through, We have put in place safety measures to protect our employees and have plans in place to support the continuity of our operation if greater challenges do arise. We currently expect our annual revenues for the year 2021 to total between $11 and $13 million. Additional to this organic growth would be the proposed acquisitions for Coke and G-Cell and Bessel Brands, which combined have trailing 12-month revenues of over $14 million. This revenue growth is expected to be supported by the changes in the Colombian cannabis law, which now allow for the export of dry flour and represent a major opportunity for flora. Details on the changes will be discussed later in the call. At this time, I would like to invite our Chief Revenue Officer, Jason Warnock, to join me in discussing the first key point we will be sharing on this call, our growth initiatives.
You're reading a preview of the FLGC Q4 2021 earnings call.
Free account.